In 207 patients over 16 with sickle cell disease and recurrent pain crises, mitapivat vs placebo achieved haemoglobin response in 41% vs 3%, but the co-primary annualised pain crisis rate was not significantly reduced (2.6 vs 3.1; p=0.12). Serious adverse events: 20% vs 29%.
RCTn = 207
Andemariam et al. Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial